CTOs on the Move

HumanTouch

www.humantouch.com

 
Human Touch is the leading provider of high-quality, innovative lifestyle products, massage chairs, and experiences that deliver life-changing benefits. We have been making people feel better for over 35 years by developing state-of-the-art massage products containing patented massage systems that replicate techniques used by massage professionals. Our wellness solutions help to reduce muscle tension and pain caused by today`s hectic lifestyle so that people can do what they do - better. Combining advanced technology and attractive design, Human Touch innovations are perfectly suited for today`s modern and traditional living spaces. Our customers include serious athletes looking to recover from intensive ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Les Buday
Director of Cybersecurity Profile

Similar Companies

Amsino International

Amsino International is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hopedale Medical Complex

Hopedale Medical Complex is a Hopedale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St Charles Parish Hospital

St Charles Parish Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Luling, LA. To find more information about St Charles Parish Hospital, please visit www.stch.net

delta flex travelers

delta flex travelers is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.